Translate Bio (Translate Bio) Pre-Tax Income : $39.7 Mil (TTM As of Jun. 2021)

View and export this data going back to 2018. Start your Free Trial

What is Translate Bio Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Translate Bio's pretax income for the three months ended in Jun. 2021 was $16.2 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jun. 2021 was $39.7 Mil. Translate Bio's pretax margin was 22.25%.

During the past 5 years, Translate Bio's highest Pretax Margin was 17.65%. The lowest was -7250.70%. And the median was -1457.96%.

Translate Bio Pre-Tax Income Historical Data

The historical data trend for Translate Bio's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio Pre-Tax Income Chart

Translate Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Pre-Tax Income

-26.70

-78.92

-102.96

-113.78

-53.79

Translate Bio Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Pre-Tax Income	Get a 7-Day Free Trial														-36.29	17.34	-20.56	26.78	16.16

Competitive Comparison of Translate Bio's Pre-Tax Income

For the Biotechnology subindustry, Translate Bio's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Translate Bio's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Translate Bio's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Translate Bio's Pre-Tax Income falls into.

Translate Bio Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Translate Bio's Pretax Income for the fiscal year that ended in Dec. 2020 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-6.74	+	-47.047	+	0	+	0	+	0
	=	-53.8

Translate Bio's Pretax Income for the quarter that ended in Jun. 2021 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	20.251	+	-4.088	+	0	+	0	+	0
	=	16.2

Pre-Tax Income for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $39.7 Mil.

Translate Bio (NAS:TBIO) Pre-Tax Income Explanation

Translate Bio's Pretax Margin for the quarter that ended in Jun. 2021 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	16.163	/	72.649
	=	22.25%

During the past 5 years, Translate Bio's highest Pretax Margin was 17.65%. The lowest was -7250.70%. And the median was -1457.96%.

Translate Bio Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Translate Bio's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Translate Bio (Translate Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Hartwell Avenue, Lexington, MA, USA, 02421

Website

http://www.translate.bio

Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Executives

Jean Francois Formela	director	C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr	director, officer: Chief Executive Officer, other: President	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess	officer: Chief Operating Officer, CLO, other: Secretary	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc.	10 percent owner	300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c.	10 percent owner	10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma	10 percent owner	10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri	director	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman	director	C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge	director	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch	director
Robert J. Meyer	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier	officer: Chief Medical Officer	255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109